診斷領域的合作與授權協議（2020-2026 年）

診斷交易中的權威基準測試

診斷領域的合作是由技術、數據和精準醫療方法驅動的，其合約結構反映了診斷平台在多個治療領域和臨床應用領域的整合。

本報告對診斷領域的 1600 多項合作與許可協議進行了全面系統的分析，清楚地展示了整個市場夥伴關係的設計、談判和執行方式，並以證據為基礎進行了闡述。

清楚了解市場標準

本報告精確地闡述了診斷領域合約的實際結構。

• 類似交易的可靠基準
• 對相關合約中的預付款、里程碑付款和特許權使用費結構進行詳細分析
• 定義切合實際的市場參數
• 清楚洞察合約條款如何因技術類型、應用情境和合作夥伴情況而異。
• 支持基於證據的評估和合約結構確定。
• 讓內部討論基於實際交易數據，而不是僅基於假設。
• 了解主要公司的交易方式
• 在技​​術主導和數據驅動的環境中，可視化合作夥伴行為模式和迭代合約結構。
• 完全透明地了解合約的結構和執行情況
• 本報告超越了表面的合約數據，提供了對底層合約文件的訪問，以便詳細了解實際協議是如何構建的。

這包括以下內容：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和付款條款
• 關鍵合約條款和保護措施
• 這種透明度對於理解診斷合作中價值、風險和控制權的分配至關重要。在平台存取、資料整合和彈性部署是關鍵考慮的領域，其重要性更為突出。
• 專為實際業務發展和策略應用而設計。

本報告廣泛用於以下用途：

• 建構和基準診斷以及技術主導交易
• 在清晰的市場環境下準備談判
• 合作機會及目的地評估
• 利用可靠且可解釋的數據支持內部策略規劃

本報告內容：

• 在診斷領域達成了超過 1600 項合作與許可協議。
• 財務條款，包括預付款、里程碑付款和特許權使用費（如已揭露）。
• 可全文搜尋的合約目錄（按公司、技術和應用）
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 合約趨勢、重大交易和活躍合約方分析。
• 診斷領域交易中可靠的、依證的參考資料。
• 本報告結合了全面的合約資料涵蓋和詳細的合約層面分析，為建立、談判和評估診斷領域的夥伴關係關係提供了可靠的、依證的參考。

目錄

執行摘要

第1章：引言

第2章：診斷領域的交易趨勢

• 過去幾年的診斷夥伴關係
• 最活躍的診斷交易方
• 診斷合約：按合約類型分類
• 診斷合約：按治療區域
• 診斷合約：按行業分類
• 診斷合約條款
  • 標題金額
  • 預付款
  • 里程碑付款
  • 權利金費率

第3章 主要診斷合約

• 按合約金額排名的前幾名診斷合約

第4章：最活躍診斷領域的締約方

• 最活躍的診斷領域的締約方
• 最活躍診斷領域中各簽約方的公司簡介

第5章 診斷合約目錄

• 診斷合約目錄

第6章 診斷合約：依技術類型分類

• 合約目錄
• 合約目錄：依公司分類的診斷合約（A-Z）
• 合約目錄：按合約類型分類的診斷合約
• 合約目錄：按治療領域分類的診斷合約
• 合約類型的定義
• 關於 Biopharma Research Ltd.
• 關於當前合作夥伴關係
• 關於現行協議
• Current Partnering 最新報告列表

The definitive benchmark for diagnostic dealmaking

Diagnostic partnering is driven by technology, data, and precision medicine approaches, with deal structures reflecting the integration of diagnostic platforms across multiple therapeutic and clinical applications.

This report provides a comprehensive and structured analysis of 1600+ diagnostic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how diagnostic deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by technology type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a technology-driven and data-centric landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within diagnostic partnerships, particularly where platform access, data integration, and multi-use applications are key considerations.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark diagnostic and technology-driven transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 1600+ diagnostic collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, technology, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for diagnostic dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how diagnostic partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in diagnostic dealmaking

• 2.1. Introduction
• 2.2. Diagnostic deals over the years
• 2.3. Most active diagnostic dealmakers
• 2.4. Diagnostic deals by deal type
• 2.5. Diagnostic deals by therapy area
• 2.6. Diagnostic deals by industry sector
• 2.7. Deal terms for diagnostic deals
  • 2.7.1 Diagnostic deals headline values
  • 2.7.2 Diagnostic deal upfront payments
  • 2.7.3 Diagnostic deal milestone payments
  • 2.7.4 Diagnostic royalty rates

Chapter 3 - Leading diagnostic deals

• 3.1. Introduction
• 3.2. Top diagnostic deals by value

Chapter 4 - Most active diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active diagnostic dealmakers
• 4.3. Most active diagnostic deals company profiles

Chapter 5 - Diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Diagnostic contracts dealmaking directory

Chapter 6 - Diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Diagnostic deals by company A-Z
• Deal directory - Diagnostic deals by deal type
• Deal directory - Diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Diagnostic deals since 2020
• Figure 2: Active diagnostic dealmaking activity since 2020
• Figure 3: Diagnostic deals by deal type since 2020
• Figure 4: Diagnostic deals by therapy area since 2020
• Figure 5: Diagnostic deals by industry sector since 2020
• Figure 6: Diagnostic deals with a headline value
• Figure 7: Diagnostic deals with an upfront value
• Figure 8: Diagnostic deals with a milestone value
• Figure 9: Diagnostic deals with a royalty rate value
• Figure 10: Top diagnostic deals by value since 2020
• Figure 11: Most active diagnostic dealmakers since 2020
• Figure 12: Diagnostic deals by technology type since 2020